In focus: the viability of real-world data and evidence
In this latest editorial feature, we bring you exclusive editorial content from industry experts exploring the feasibility, credibility and validity of real-world data studies. We hope you enjoy the feature and encourage you to share any feedback by tweeting us, @EvidenceBaseFSG, or emailing our editor!
How can we assess the feasibility of real-world data studies? How may the industry’s perspective on real-world evidence differ from that of other key stakeholders? What steps must be taken to boost the reputability and validity of real-world evidence, to ensure it is a valuable resource for use in regulatory and healthcare decision-making?
Discover answers to these questions and more in our exclusive ‘In focus‘ content below!
Interested in working with The Evidence Base® on your own campaign? Contact us today>>>
In these ‘In focus’ exclusives, Jefferson Tea (Takeda Canada Inc., ON, Canada) and Manuela Di Fusco (Pfizer, NY, USA) share their expert industry insight on the validity and feasibility of real-world data studies, as well as what must be done to enhance these.
Jefferson discusses his presentation delivered at the Patient Registries, Real-World Evidence and HEOR meeting (27–28 January 2020; Miami, FL, USA), on how and why the industry perception of real-world evidence may differ from that of other stakeholders, whilst Manuela shares a personal editorial opinion on how to assess the feasibility of real-world data and real-world data studies.
Manuela is a member of our Expert Panel on The Evidence Base® – discover what a typical day on the job entails for Manuela in this interview conducted in celebration of International Women’s Day 2020>>
We are delighted to share the second episode of our podcast series on The Evidence Base, featuring Michael Moran (Pfizer, Berlin, Germany).
In this episode, Editor of The Evidence Base, Ilana Landau, explores the differential benefits and challenges associated with utilizing real-world versus randomized controlled trial data.
Listen now for exclusive insight into Michael’s own work and experience comparing the outcomes observed from analyzing clinical trial and observational, real-world data. Are the outcomes comparable? What are the implications of these findings?